CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Immunological profilingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2394 Surveys Wiki 1.00
drug2287 Specimen Collection Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Immunological Profiling of Patients With COVID-19 in Respiratory Distress

The study investigators hypothesize that the pneumonia arising in patients with COVID-19 is largely of immunopathological origin. The investigators will therefore seek to define the immune activation phenotype of patients in respiratory distress and to see if this immune signature is predictive of mortality. Finally, the investigators will look for overproduced inflammatory mediators to identify potential therapeutic targets.

NCT04351711 SARS-CoV-2 Covid-19 Other: Immunological profiling

Primary Outcomes

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry

Measure: Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 27 (naïve/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry

Measure: Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry

Measure: Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Description: Quantified by flow cytometry; % variation / normal values

Measure: Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled)

Time: Day 0

Secondary Outcomes

Description: Difference in expression of the biomarkers assayed for primary outcome

Measure: Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 before any respiratory distress against that of 150 volunteers from the general population (data already existing).

Time: Day 0

Description: Difference in expression of the biomarkers assayed for primary outcome

Measure: Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 with respiratory failure against versus those without respiratory failure

Time: Day 0

Measure: Mortality rate

Time: End of study (2021)

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of E-selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Granulocyte Macrophage Colony-Stimulating Factor levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of InterCellular Adhesion Molecule levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interferon alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interferon gamma levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-4 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-6 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-8 (C-X-C motif ligand 8) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-10 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-12p70 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-13 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Interleukin-17A levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Induced Protein -10 (C-X-C motif chemokine 10) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Monocyte Chemoattractant Protein-1 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Macrophage Inflammatory Protein-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Macrophage Inflammatory Protein -1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of P-Selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: quantified by Luminex (TruCulture tube system (Myriad RBM))

Measure: Comparison of Tumor necrosis factor alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects

Time: Day 0

Description: Difference in expression of the 20 inflammatory markers described in outcomes 51-70

Measure: Identify inflammatory mediators over-produced by the PBMC of patients with COVID-19 before respiratory distress

Time: Day 0

Description: Difference in expression of the 20 inflammatory markers described in outcomes 51-70

Measure: Compare the inflammatory mediators over-produced by the peripheral blood mononuclear cells of patients with COVID-19 with versus without respiratory failure

Time: Day 0

Description: Performed at the Institut de Génétique Humaine (Montpellier)

Measure: Comparison of transcriptome from peripheral blood mononuclear cells from 12 patients with respiratory failure (from intensive care ward) and 10 without (normal hospitalization)

Time: Day 0


No related HPO nodes (Using clinical trials)